The immune inhibitory receptor NKG2A is of emerging interest in cancer immunotherapy, with antibodies that target and interrupt NKG2A, in combination with PD‐L1 blockade, yielding promising antitumor responses in ongoing clinical trials. The gene discussed is KLRC1; the disease is cancer.